Pharmaceutical giant declines to comment on local job loss reports
The firm has around 78,400 staff worldwide Pic: iStock
A pharmaceutical giant operating in the county has declined to comment on reports of job losses in Roscommon.
Yesterday, the Westmeath Independent reported that Novo Nordisk is making approximately 75 workers redundant at its Monksland facility. These are believed to take effect in October and are in addition to some 40 voluntary redundancies announced in recent weeks, the paper said.
When contacted the company said that it has previously announced that the total number of intended workforce reductions globally is approximately 9,000.
“Out of respect for the employees involved, we will not share additional details about individual sites or areas. This process takes time, and our highest priority is to support our employees,” a spokesperson said.
“We are announcing a company-wide transformation to simplify our organisation, improve decision-making speed, and reallocate resources towards the company’s growth opportunities in diabetes and obesity. As part of this change, we are assessing all business areas and regions to simplify structures, reduce duplication, and sharpen focus. These organisational changes will allow Novo Nordisk’s teams to work more efficiently and focus on what matters most: driving innovation and reaching many more patients.” The maker of weight-loss drugs Ozempic and Wegovy, Novo Nordisk employs about 400 at its plant in Monksland.
Last year, Roscommon County Council sold just over eleven acres of land to the company for €1.55m to accommodate its expansion plans.
In 2023, the Danish firm purchased Alkermes’ Monksland facility for $92.5m.
